ImmunologyNephrologyNeurologyCardiovascularPain ManagementDiabetesOncologyVaccinesCentral Nervous SystemHealth Care
Description
Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products.
Business Segments
The company operates through various business segments that encompass a wide range of pharm…
Analysis
Hope premium
Zydus Lifesciences Limited is priced well ahead of what the underlying numbers justify, a pattern we describe as a hope premium. Worth noting: the cash the business generates has lagged behind what the income statement shows.
On valuation, the picture is expensive. The owner-earnings multiple stands at 32.8×; owner earnings: the cash an owner could take out each year. The implied growth embedded in that price is around 13% a year, against analyst forecasts of 7%. The gap between price and consensus is worth watching: demanding expectations.
Growth is moderate; the safety picture is adequate. The company scores 17/20 on our value-creation score: strong value creator.
Flags to be aware of: Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.
360° rank · history
1007550250
Jan 202335
25
2023202420252026
All-time high
93
Jan 2025
All-time low
23
Mar 2026
Average rank
52
across all years
Detailed & Historical Ranks
Deep dive into 15 detailed ranks and 3 years of history.
Current202520242023
Price/Sales
36
50
61
70
Price/Earnings
48
73
68
74
Price/Book
35
58
69
69
Dividend Yield
51
44
45
52
Value (overall)
46
67
67
75
Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.